Lung carcinoma predictive biomarker testing by immunoperoxidase stains in cytology and small biopsy specimens: Advantages and limitations

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 12, 2016, Pages 1331-1337

  Zhou, Fang ^a   Moreira, Andre L ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

BIOPSY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ANALYSIS; ENZYME IMMUNOASSAY; GENE REARRANGEMENT; GENETICS; HUMAN; LABORATORY AUTOMATION; LUNG; LUNG NEOPLASMS; METABOLISM; MOLECULAR DIAGNOSIS; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TRENDS;

AUTOMATION, LABORATORY; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CYTOGENETIC ANALYSIS; GENE REARRANGEMENT; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 85003819945     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2016-0157-RA     Document Type: Review

References (66)

1. Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010;5(4):411-414.
2. Lim C, Sung M, Shepherd FA, et al. Patients with advanced non-small cell lung cancer: are research biopsies a barrier to participation in clinical trials? J Thorac Oncol. 2016;11(1):79-84.
3. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6(3):451-458.
4. Chen H, Luthra R, Goswami RS, Singh RR, Roy-Chowdhuri S. Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies. Cancers (Basel). 2015;7(3):1699-1715.
5. Singh VM, Salunga RC, Huang VJ, et al. Analysis of the effect of various decalcification agents on the quantity and quality of nucleic acid (DNA and RNA) recovered from bone biopsies. Ann Diagn Pathol. 2013;17(4):322-326.
6. Rosenblum F, Hutchinson LM, Garver J, Woda B, Cosar E, Kurian EM. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma. Cancer Cytopathol. 2014;122(11):810-821.
7. Moreira AL, Hasanovic A. Molecular characterization by immunocytochemistry of lung adenocarcinoma on cytology specimens. Acta Cytol. 2012;56(6):603-610.
8. Moreira AL, Saqi A, eds. Diagnosing Non-Small Cell Carcinoma in Small Biopsy and Cytology. New York, NY: Springer; 2015.
9. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26(12):1545-1553.
10. Fischer AH, Schwartz MR, Moriarty AT, et al. Immunohistochemistry practices of cytopathology laboratories: a survey of participants in the College of American Pathologists Nongynecologic Cytopathology Education Program. Arch Pathol Lab Med. 2014;138(9):1167-1172.
11. Moriarty AT, Nayar R, Auger M, et al. Nongynecologic cytology practice patterns: a survey of participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytopathology. Arch Pathol Lab Med. 2013;138(7):885-889.
12. Sturgis CD, Marshall CB, Barkan GA, et al. Respiratory cytology - current trends including endobronchial ultrasound-guided biopsy and electromagnetic navigational bronchoscopy: analysis of data from a 2013 supplemental survey of participants in the College of American Pathologists Interlaboratory Comparison Program in Nongynecologic Cytology. Arch Pathol Lab Med. 2016;140(1):22-28.
13. Roy-Chowdhuri S, Goswami RS, Chen H, et al. Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015;123(11):659-668.
14. Treece AL, Montgomery ND, Patel NM, et al. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas [published online ahead of print February 16, 2016]. Cancer Cytopathol. 2016;124(6):406-414. doi:10.1002/cncy.21699.
15. Wei S, Lieberman D, Morrissette JJ, Baloch ZW, Roth DB, McGrath C. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: an institutional experience [published online ahead of print December 18, 2015]. Cancer Cytopathol. 2016;124(5):324-329. doi:10.1002/cncy.21666.
16. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010;16(20):4938-4945.
17. Savic S, Bode B, Diebold J, et al. Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol. 2013;8(8):1004-1011.
18. Hasanovic A, Ang D, Moreira AL, Zakowski MF. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer. 2012;77(2):299-305.
19. Taylor CR, Rudbeck L, eds. Immunohistochemical Staining Methods. 6th ed. Glostrup, Denmark: Dako Denmark A/S; 2013.
20. Thavarajah R, Mudimbaimannar VK, Elizabeth J, Rao UK, Ranganathan K. Chemical and physical basics of routine formaldehyde fixation. J Oral Maxillofac Pathol. 2012;16(3):400-405.
21. Sauter JL, Grogg KL, Vrana JA, Law ME, Halvorson JL, Henry MR. Young investigator challenge: validation and optimization of immunohistochemistry protocols for use on Cellient cell block specimens. Cancer Cytopathol. 2016;124(2):89-100.
22. Kinsella MD, Birdsong GG, Siddiqui MT, Cohen C, Hanley KZ. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples. Diagn Cytopathol. 2013;41(3):192-198.
23. Fitzgibbons PL, Bradley LA, Fatheree LA, et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2014;138(11):1432-1443.
24. Cutz JC, Craddock KJ, Torlakovic E, et al. Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer. J Thorac Oncol. 2014;9(9):1255-1263.
25. Sholl LM, Aisner DL, Allen TC, et al. Programmed death ligand-1 immunohistochemistry - a new challenge for pathologists. Arch Pathol Lab Med. 2016;140(4):341-344.
26. Conde E, Suarez-Gauthier A, Benito A, et al. Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry. PLoS One. 2014;9(9):e107200.
27. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256.
28. Layfield LJ, Frazier S, Esebua M, Schmidt RL. Interobserver reproducibility for HER2/neu immunohistochemistry: a comparison of reproducibility for the HercepTest and the 4B5 antibody clone. Pathol Res Pract. 2016;212(3):190-195.
29. Zito Marino F, Liguori G, Aquino G, et al. Intratumor heterogeneity of ALK-rearrangements and homogeneity of EGFR-mutations in mixed lung adenocarcinoma. PLoS One. 2015;10(9):e0139264.
30. Park S, Koh J, Kim DW, et al. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer. 2015;90(3):381-387.
31. Boccaccio C, Comoglio PM. MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr Opin Cell Biol. 2014;31:98-105. doi:10.1016/j.ceb.2014.09.008.
32. Pandya D, Jungbluth A, Rekhtman N, Moreira AL. Determination of PTEN and c-MET status for lung adenocarcinoma is variable in biopsy and concurrent excisional specimens. Lab Invest. 2015;95(S1):486A.
33. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12(2):169-176.
34. Seo AN, Park TI, Jin Y, et al. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746-A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer. 2014;83(3):316-323.
35. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16(12):3163-3170.
36. Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res. 2010;16(13):3349-3355.
37. Kato Y, Peled N, Wynes MW, et al. Novel epidermal growth factor receptor mutation-specific antbodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol. 2010;5(10):1551-1518.
38. Kozu Y, Tsuta K, Kohno T, et al. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer. 2011;73(1):45-50.
39. Nakamura H, Mochizuki A, Shinmyo T, et al. Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res. 2010;30(12):5233-5238.
40. Simonetti S, Molina MA, Queralt C, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med. 2010;8:135.
41. Jiang G, Fan C, Zhang X, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS One. 2013;8(3):e59183.
42. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
43. Kawahara A, Azuma K, Sumi A, et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011;74(1):35-40.
44. Rooper LM, Nikolskaia O, Carter J, Ning Y, Lin MT, Maleki Z. A single EBUS-TBNA procedure can support a large panel of immunohistochemical stains, specific diagnostic subtyping, and multiple gene analyses in the majority of non-small cell lung cancer cases [published online ahead of print January 18, 2016]. Hum Pathol. 2016;51:139-145. doi:10.1016/j.humpath.2015.12.025.
45. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
46. Minca EC, Portier BP, Wang Z, et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn. 2013;15(3):341-346.
47. Wang W, Tang Y, Li J, Jiang L, Jiang Y, Su X. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization. Cancer Cytopathol. 2015;123(2):117-122.
48. Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11(4):487-495.
49. Le Quesne J, Maurya M, Yancheva SG, et al. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material. J Thorac Oncol. 2014;9(6):769-774.
50. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010;16(5):1561-1571.
51. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6(8):1359-1366.
52. Tsao MSH, Hirsch FR, Yatabe Y, eds. IASLC Atlas of ALK Testing in Lung Cancer. Aurora, CO: IASLC Press; 2013.
53. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014;83(2):168-173.
54. Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013;37(9):1441-1449.
55. Kinno T, Tsuta K, Shiraishi K, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol. 2014;25(1):138-142.
56. Liu SV, Subramaniam D, Cyriac GC, Abdul-Khalek FJ, Giaccone G. Emerging protein kinase inhibitors for non-small cell lung cancer. Expert Opin Emerg Drugs. 2014;19(1):51-65.
57. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol. 2013;24(3):742-748.
58. Ilie MI, Lassalle S, Long-Mira E, et al. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Thyroid. 2014;24(5):858-866.
59. Sasaki H, Shimizu S, Tani Y, et al. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer. 2013;82(1):51-54.
60. Lee SR, Yim H, Han JH, et al. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases. Am J Clin Pathol. 2015;143(3):437-444.
61. Fnais N, Soobiah C, Al-Qahtani K, et al. Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol. 2015;46(10):1443-1454.
62. Wobker SE, Kim LT, Hackman TG, Dodd LG. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma. Cancer Cytopathol. 2015;123(9):531-539.
63. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;23(8):541-549.
64. Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy [published online ahead of print March 16, 2016]. The Oncologist. 2016;21:1-9. doi:10.1634/theoncologist.20150507.
65. Food and Drug Administration. P150025 Trade/device name: PD-L1 IHC 28-8 pharmDx. 2016 vol; 2015. http://www.accessdata.fda.gov/cdrh-docs/pdf15/P150025a.pdf.
66. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiated multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol. 2009;33(12):1752-1764.